Clinical Trial Update: TART - Troglitazone Atherosclerosis Regression Trial [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for the Troglitazone Atherosclerosis Regression Trial (TART) in patients with atherosclerosis and diabetes, with Phase 2/3 completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Diabetes Mellitus

Drugs mentioned

• Rezulin (Troglitazone)

Snippet

Sponsor: Parke-Davis | Conditions: Atherosclerosis, Diabetes Mellitus | Phase 2, Phase 3 | Status: COMPLETED